Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.59 |
| ▸ | GSK3B | P49841 | 12/20 | 0.59 |
| ▸ | WNT1 | P04628 | 6/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481248 | 0.89 | MKNK1 (0.62) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25605337 | 0.83 | MKNK1 (0.64) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25645546 | 0.82 | MKNK1 (0.66) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL31472544 | 0.82 | MKNK1 (0.66) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25437833 | 0.81 | MKNK1 (0.64) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL31380017 | 0.81 | MKNK1 (0.64) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25612167 | 0.81 | MKNK1 (0.64) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25611765 | 0.81 | DYRK1A (0.74) | MKNK1DYRK1AGSK3BWNT1 | |
| SCHEMBL31271579 | 0.80 | MKNK1 (0.63) | MKNK1DYRK1AGSK3BWNT1CCNE2 | |
| SCHEMBL25610637 | 0.80 | MKNK1 (0.63) | MKNK1DYRK1AGSK3BWNT1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | MKNK1 105/4885DYRK1A 1/4885GSK3B 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.